anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Conditions such as hypermobility spectrum disorders (HSD) and Ehlers-Danlos syndrome (EDS) are most often diagnosed when an individual has joint flexibility beyond the normal physiological limits. Additional characteristics and symptoms include pain and fatigue with individuals also being more likely to report feelings of anxiety and depression. Due to the varied presentation of these conditions, there is a lack of understanding amongst the various healthcare professionals (HCPs) individuals present to, leading to delayed diagnoses and negative experiences for the individuals themselves. This scoping review therefore aims to map the known biopsychosocial impact of adults with HSD and EDS.
METHODS: The scoping review will follow the six-step framework as outlined by Arskey and O'Malley and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) checklist. The search will be conducted using the following databases: AMED, CINAHL, Cochrane Library, Embase, MEDLINE, PsycINFO, PubMed PEDro. Full-text published articles in the English language (excluding literature and systematic reviews) with adult samples (over the age of 18 years) and a diagnosis of a HSD or EDS, published between 2012 and 2022, will be included in the review.
DISCUSSION: This review will aim to explore the existing literature for the reported biopsychosocial impact of adults with a HSD or EDS. It will also aim to further acknowledge the gaps in understanding of the condition, how the condition and the impact of the condition is being measured and what HCPs are involved in supporting such individuals. These gaps will be used to inform a future systematic review. It is the overall goal to increase the knowledge of HCPs and the quality of life of adults living with a joint hypermobility condition.
<P>PROBLEM TO BE SOLVED: To provide an active component capable of stimulating the direct or indirect expression of type 2 and/or type 3 human β-defensin without inducing inflammation, irritation or hypersensitive reaction.  <P>SOLUTION: The increase of the amount of β-defensin in human skin prevents the pathogenic specific species (Staphylococcus aureus) from invading excessively into an ecosystem of a body, and contributes for protecting the skin and keeping it to be healthy. The active component is selected from the roots of mugwort, horseweed, bark of a red-berried elder, etc., or their extract, α-MSH, one of its constituting peptides and substance resembling to the peptides. The active components can be used as a cosmetic composition containing the same by 0.01-10 wt. %. Also, the active components can be used as medicinally permissible excipients. As the method for screening the active components without causing inflammation, a skin bio-test method using epithelial cells such as keratinocytes, cornecytes, etc., is cited.  <P>COPYRIGHT: (C)2004,JPO
Modern lifestyle has dramatically changed the daily rhythms of life. Physical activity, diet and light exposure are no longer restricted to daytime hours due to increased shift work. Recent scientific reports have shown that shift work leads to disruption of circadian rhythms and promotes diabetes, obesity and cardiovascular disease. Until now only few studies investigating circadian rhythm disturbances in the context of type 2 diabetes and obesity have been conducted in man. Thus, knowledge of the molecular pathways and the responsibles genes in man are missing and have been identified only in animal studies.

The objective of the project is to achieve breakthroughs in the understanding of the causality between inner clock rhythm disturbances and the development of type 2 diabetes and obesity. The provided data on the interaction between genes, epigenetics, metabolism, cardiovascular function and the internal clock are intended to contribute to identify novel biomarkers and novel therapeutic approaches focusing on circadian rhythms to reduce the occurence of diabetes and obesity in shift worker.
Composite particle including the following: (1) a nanocrystal of an organic compound, and (2) a block copolymer associated with one or more surfaces of the nanocrystal of an organic compound. The organic compound, in some embodiments, is a pharmaceutical compound, a therapeutic compound, and/or a bioactive compound. The block copolymer may be a block copolymer with at least one hydrophilic poly(2-oxazoline) block. Pharmaceutical compositions may include these composite particles. The pharmaceutical compositions may include a dispersion that has an aqueous or aqueous-based continuous phase and a dispersed phase that includes the composite particles. The dispersion may be administered to sick patients, including those diagnosed with or exhibiting symptoms of COVID-19. For example, the dispersion may be aerosolized, and a patient may inhale the aerosol.
PURPOSE OF REVIEW: Chronic pelvic pain is much of a burden to those who suffer from it. Additionally, in many patients medical doctors, such as urologists are unable to identify a cause or clear pathology that can explain the pain. Still numerous patients and doctors keep on searching for a cause, focussing particularly on the pelvic organs. Lots of diagnostics and treatment methods are used but often without success. In recent years, we have gained increased insight into the mechanisms of pain and adapted the terminology accordingly.
RECENT FINDINGS: Two aspects of chronic pelvic pain have gained more attention. First, the myofascial aspects, especially the role of the pelvic floor muscles in maintaining the pain and as a therapeutic option. Second, the role of the brain and the psychological aspects intertwine with the pain and its consequences also open up for alternative management options. In terminology chronic pain is now included in the ICD-11, a historical change. Introducing chronic primary pain (no cause found) helps us to look away from the organ and deal with the patient as a whole human being.
SUMMARY: The findings reported here are helpful for your daily practice. Looking from a broad perspective gives the patient the feeling of being seen and heard. Working together in a multidisciplinary team makes your work easier and gives more satisfaction.
VIDEO ABSTRACT: http://links.lww.com/COU/A44.
Coronary artery bypass graft (CABG) surgery is one of the most common elective surgical procedure. In total 40.000 CABG´s have been performed yearly in Germany in 2012 and 2013 which presents 60% of all cardiac surgical interventions. Coronary artery bypass grafting is performed for patients with coronary artery disease (CAD) to improve quality of life and to reduce cardiac-related mortality. CAD is the most leading cause of mortality in the Western world as well as in developing countries and it is the most common cause of heart failure. CABG was introduced in the 1960s. CABG operation has become the most studied intervention in the history of surgery. It is highly effective in the treatment of severe angina and it delays unfavorable events such as death, myocardial infarction and recurrence of angina in comparison to other treatment forms. There is a general agreement that already in the early postoperative period CABG surgery improves the disease in patients with symptomatic left main coronary artery stenosis or stenosis of the three main coronary vessels.
To explore the influencing factors of singletons with macrosomia, and to develop interventions for the prevention of macrosomia. A retrospective cohort study was conducted on 26,379 pregnant women who established the Maternal and Child Health Record and gave birth from January 1, 2019 to December 31, 2019 in a community health service center in Haidian district, Beijing. The study analyzed factors such as maternal age, ethnicity, education level, prepregnancy body mass index (BMI), parity, folic acid supplementation, gestational diabetes mellitus, gestational hyper, hypothyroidism in pregnancy (including subhypothyroidism), hyperthyroidism in pregnancy, and infant gender. Univariate analysis was performed using the χ2 test, and multivariate analysis was performed using non-conditional multivariate logistic regression analysis. Out of 26,379 live births, 5.8% (1522/26,379) were macrosomia and 94.2% (24,857/26,379) were non-macrosomia. Univariate analysis revealed that maternal age, prepregnancy BMI, education level, parity, hypothyroidism during pregnancy, and infant gender were identified as influencing factors for macrosomia (P < .05). Multivariate analysis showed that maternal age ≥ 35 years, education level of high school or below, pre-pregnancy BMI, hypothyroidism, male infant, and parity were all influencing factors for macrosomia (P < .05). Prepregnancy overweight or obesity, male infants, multiparity, and low education level are risk factors for macrosomia. Multiple factors can contribute to macrosomia, and therefore, maternal health care should be strengthened, and early interventions should be taken for the above-mentioned factors in the local area.
The present invention relates to a novel Polypeptide Drug Conjugate (PDC). The invention also provides a PDC-DNA aptamer induced self-assembly body which is formed by self-assembly of the designed PDC and the DAC aptamer AS 1411. The invention also provides that the PDC and the DNA aptamer can be mixed and incubated at normal temperature to be self-assembled into microspheres with the diameter not more than 100nm, and the nano microspheres are positively charged. The invention also provides a method for effectively carrying the nucleic acid medicament into the tumor cell nucleus by using the PDC-DNA aptamer self-assembly body. The invention also provides application of the PDC-DNA aptamer in treating malignant ovarian cancer, and the PDC-DNA aptamer can achieve the aim of resisting tumors from various signal paths. The invention also provides the self-assembly body of the polypeptide-nucleic acid, which has better biocompatibility.
Permanent pacing with right ventricular stimulation is the standard method used in patients with bradyarrhythmia, and recommended by current international guidelines because it is associated with improved clinical outcomes. The extent of right ventricular pacing (RVP) varies between patients and many individuals tolerate a high proportion of RVP without complications. However, chronic RVP may cause electrical and mechanical dyssynchrony that may lead to impaired left ventricular ejection fraction (LVEF). Dyssynchronous ventricles require more oxygen to generate the same amount of mechanical work and the consequence is a decline in the efficieny of myocardial contraction. RV septal pacing (RVS) is thought to allow more physiological LV depolarisation, than RV apical pacing (RVA) with preservation of LV function. However, there are conflicting data on its benefits, and the recently completed Protect-Pace (The protection of LV function during RV pacing) study showed both RVA and non-RVA pacing to have a small adverse effect on EF in patients with preserved LV function, but no difference between the methods. The effect of RV pacing on RV function has not been evaluated systematically, with most studies focusing on tricuspid regurgitation (TR) as the outcome of interest. Echocardiographic assessment of LV dyssynchrony has been extensively used because it is noninvasive, widely available, and has no known risk or side effect. Speckle tracking echocardiography is a novel echocardiographic technique without the angle dependence of an ultrasound beam and is able to measure regional deformation in any direction in the LV and RV, that can detect subtle myocardial dysfunction because it is more sensitive compared with conventional parameters, Furthermore, strain imaging can display the timing and extent of myocardial thickening and stretching so that it is well suited to estimate the amount of inefficient dyssynchronous contraction. Global Longitudinal Strain (GLS) and LV mechanical function and dyssynchrony assessment by speckle-tracking echocardiography (STE) enables us to detect subclinical LV dysfunction. And also a very attractive clinical tool for the assessment of right ventricular (RV) systolic performance, providing incremental diagnostic and prognostic information over the traditional indices of RV function, Among various imaging modalities, echocardiography is currently the method of choice for clinical assessment of RV longitudinal strain (RVLS). The methodology of speckle-tracking echocardiography to obtain RVLS has been recently standardized and demonstrated to be feasible, accurate, and robust for clinical use. Inter-technique and inter-vendor comparability and reliability of RVLS are improving. RVLS is advantageous because it is more sensitive to subtle changes in myocardial function than conventional parameters used to assess RV function (i.e. tricuspid annular plane systolic excursion, tissue Doppler systolic velocity, fractional area change, or RV ejection fraction) representing a sensitive tool for the long-term follow-up of patients.
The invention relates to a method for a tetanus toxin receptor binding domain Hc to be subjected to high-level soluble expression in Escherichia coli through nucleotide sequence optimization. According to the sequencing result of a domestic C.Tetani virulent strain CMCC64008, the tetanus toxin receptor binding domain Hc sequence is analyzed and optimized, the optimized sequence is SEQ ID No.1 and the coded protein sequence is SEQ ID No.2. The synthesized Hc gene is linked into an expression vector pET32a(+) after undergoing double enzyme digestion, the recombinant Hc is subjected to high soluble expression in Escherichia coli and the target protein accounts for about 46% of the total protein in the supernatant undergoing bacteriociasis. After QFF column purification, phenyl hydrophobic column purification and SP column purification, the purity of the target protein can be more than 95% and the yield thereof is more than 300mg/L. The recombinant protein prepared by the method of the invention has good immunogenicity, can induce the mice to produce high-titre protective antibodies and can resist attack of high-dose lethal toxins. The method has extensive application prospect in large-scale high-level preparation of the tetanus toxin recombinant subunit vaccine Hc.
The present invention belongs to the technical field of Chinese patent medicines. The Chinese patent medicine of the current medicine material markets, which is used for treating traumatic injuries and activating blood circulation to remove blood stasis, has the disadvantages of low therapeutic effect and slow effect. The special medicine for activating blood circulation to remove blood stasis is developed for preparing for Beijing 2008 olympic games, striving for the first total number of gold medals in the world and helping the injured athletes of China recover. The medicine of the present invention is prepared from hiraute shiny bugleweed herb, cape jasmine fruit, dragon blood, rhubarb, safflower, olibanum, myrrh, red sage root, peach seed, catechu, cercis bark, rosewood, etc. The success or failure key of the medicine lies in the quality of the dragon blood. The medicine can be used by external application or oral administration, wherein the external application is mainly used for treating traumatic injuries. The principle of the medicine comprises dredging the blood vessels, removing static blood, activating blood circulation and making disease evils and static blood remove from the interior to the exterior. Patients can be recovered by absorbing the medicine, pain can be resisted by the smooth flow of qi, and cytoclasis caused by the stagnation of static blood is avoided. The medicine is mainly used for treating traumatic injuries, next for coronary heart diseases, various kinds of thrombus and various rheumatoid diseases, has the advantages of safety, obvious effect, wide medicine source, low cost and simple preparation process, and is suitable for the standby and adoption of athletes of china.
PURPOSE: A capsule for measuring flow information using X-ray and a measuring method are provided to measure flow in a human body in a micrometer accuracy. CONSTITUTION: A capsule(1) for measuring flow information using X-ray comprises inner wall material(12) and outer wall material(11). The capsule contains biocompatible polymer, organic contrast agent, and cross linking agent. The organic contrast agent is iodine-based contrast agent, barium-based organic contrast agent, or mixture thereof. The cross linking agent is glutaaldehyde. A method for measuring flow information using X-ray is flow visualization or X-ray particle image velocimetry(PIV).
[MEANS FOR SOLVING PROBLEMS] Attention has been drawn to Indian lotus among plants, and an Indian lotus extract has been obtained. Effect of the addition of Indian lotus extract on enzymic reaction has been estimated by carrying out reaction with .alpha.-glucosidase and sucrose as its substrate. As a result, it has become apparent that the Indian lotus extract has an .alpha.-glucosidase inhibiting activity. Further, the Indian lotus extract and sucrose have been administered to mice, and the blood sugar level thereof has been measured. As a result, it has become apparent that the blood sugar level is restricted by the Indian lotus extract. Therefore, it has become apparent that the Indian lotus extract has an .alpha.-glucosidase inhibiting activity, and it has been found that the Indian lotus extract can be used in controlling of the blood sugar level.
Novel heterocyclically substituted 5-sulphamoylbenzoic acid derivatives of the accompanying formula I, in which the symbols R<1>, R<2>, X and A have the meaning given in Patent Claim 1, are prepared by introducing the radical X into appropriate 3-nitro-5-sulphamoylbenzoic acids or their esters, which carry a halogen atom in the 4-position and whose 5-sulphamoyl group is protected, reducing the reaction product to the corresponding 3-amino compound, reacting this with dicarboxylic acid derivatives, reducing the 3-imido or 3-amido compounds thus obtained and hydrolysing the reaction product thus obtained to remove the protective group B and the ester group R<3>. The alkyl radicals R<2> can then be introduced by alkylation. Starting from the compounds of the formula I prepared according to the invention, in which X denotes a -SR<4> group, the corresponding compounds in which X denotes a -SOR<4> or -SO2R<4> group are obtained by oxidation. The novel compounds are highly active saluretics and diuretics. They are used mainly for the treatment of oedematous diseases of various origins. <IMAGE>
In healthy volunteers and patients with IBS, alosetron (2 mg orally, twice daily for 8 days) increased colonic transit time without affecting orocecal transit time. In healthy volunteers, alosetron also increased basal jejunal water and sodium absorption after a single 4 mg dose. In patients with IBS, multiple oral dosages of alosetron (4 mg twice daily for 6.5 days) significantly increased colonic compliance.

Single oral doses of alosetron administered to healthy men produced a dose-dependent reduction in the flare response seen after intradermal injection of serotonin. Urinary 6-β-hydroxycortisol excretion decreased by 52% in elderly subjects after 27.5 days of alosetron 2 mg administered orally twice daily. This decrease was not statistically significant. In another study utilizing alosetron 1 mg administered orally twice daily for 4 days, there was a significant decrease in urinary 6-β-hydroxycortisol excretion. However, there was no change in the ratio of 6-β-hydroxycortisol to cortisol, indicating a possible decrease in cortisol production. The clinical significance of these findings is unknown.
BACKGROUND: Preeclampsia in a first pregnancy is a strong risk factor for preeclampsia in a second pregnancy. Whether chronic hypertension developed after a first pregnancy (interpregnancy hypertension) affects the recurrence risk of preeclampsia is unknown.
METHODS: This is a population-based cohort study of 391,645 women with their first and second singleton births between 2006 and 2017. Exposure groups were women with preeclampsia in their first pregnancy, interpregnancy hypertension, or both risk factors. Women with neither risk factor were used as a reference group. We calculated the adjusted relative risk (aRR) with 95% confidence intervals (CIs) for overall preeclampsia in the second pregnancy as well as preterm (<37 gestational weeks) and term (≥37 gestational weeks) subgroups of the disease.
RESULTS: Women with preeclampsia in their first pregnancy who did or did not develop interpregnancy hypertension had rates of preeclampsia in their second pregnancy of 21.5% and 13.6%, respectively. In the same population, the corresponding rates of preterm preeclampsia were 5.5% and 2.6%, respectively. After adjusting for maternal factors, women with preeclampsia in their first pregnancy who developed interpregnancy hypertension and those who did not have almost the same risk of overall preeclampsia in their second pregnancy (aRRs with 95% CIs: 14.51; 11.77-17.89 and 12.83; 12.09-13.62, respectively). However, preeclampsia in the first pregnancy and interpregnancy hypertension had a synergistic interaction on the outcome of preterm preeclampsia (aRR with 95% CI 26.66; 17.44-40.80).
CONCLUSIONS: Women with previous preeclampsia who developed interpregnancy hypertension had a very high rate of preterm preeclampsia in a second pregnancy, and the two risk factors had a synergistic interaction.
This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
BACKGROUND: Mex-3 RNA binding family members are well-established to be important in cancer development and progression. However, the functions of Mex-3 RNA binding family member A (MEX3A) in colorectal cancer (CRC) metastasis remain poorly understood. In this study, we aim to reveal the function and the mechanism of MEX3A in promoting CRC metastasis.
METHODS: We used multiple databases including TCGA database, UALCAN, LinkedOmics, CancerSEA, GeneMANIA and STRING database to investigate the expression, the functions and underlying molecular mechanism of MEX3A in CRC. Multiple experimental methods were adapted to determine the study, including real-time PCR (qPCR), immunohistochemistry (IHC), western blot (WB), transfection, transwell migration and invasion assays, immunofluorescence (IF).
RESULTS: We found that MEX3A was significantly upregulated and correlated to tumor stage and lymph nodal metastasis in CRC through bioinformatics analysis and tissue immunohistochemistry (IHC). The higher expression of MEX3A in CRC correlated with poor recurrence-free survival (RFS) and overall survival (OS). In vitro studies showed that knockdown of MEX3A suppressed EMT transition, invasion and metastasis of CRC cells. Mechanistically, we revealed that MEX3A promotes epithelial-mesenchymal transition (EMT), invasion and metastasis of CRC cells by upregulating the Wnt/β-catenin signaling pathway.
CONCLUSION: In conclusion, our study reveals that MEX3A promotes CRC migration, invasion and EMT via regulating the Wnt/β-catenin signaling pathway and could be a novel therapeutic target for this patient population.